Viridian Therapeutics, Inc.\DE (VRDN) EBT Margin (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly EBT Margin of 79261.7% for Q1 2026, up 5151746.0% year-over-year from N/an in Q1 2025, and down 5.35% quarter-over-quarter from 75234.09% in Q4 2025.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) EBT Margin (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's EBT Margin history runs 14 years deep, the most recent figure standing at 79261.7% for Q1 2026.
- In Q1 2026, EBT Margin rose 5151746.0% year-over-year to 79261.7%; the TTM figure through Mar 2026 stood at 504.51% (up 11131735.0% YoY), while the FY2025 annual figure was 921.42%, up 15667758.0% from the prior year.
- EBT Margin for Q1 2026 stood at 79261.7%, down from 75234.09% in the prior quarter.
- The five-year high for EBT Margin was 49.67% in Q3 2025, with the low at 148888.0% in Q2 2025.
- The 5-year median for EBT Margin is 76476.39% (2023), against an average of 72374.11%.
- The sharpest annual moves came in 2023 and 2025: EBT Margin tumbled 7347718 bps in 2023, then surged 10633289 bps in 2025.
- Viridian Therapeutics, Inc.\DE's EBT Margin stood at 43438.1% in 2022, then tumbled by 169 bps to 116915.28% in 2023, then climbed by 6 bps to 109850.0% in 2024, then jumped by 32 bps to 75234.09% in 2025, then fell by 5 bps to 79261.7% in 2026.
- Business Quant data shows VRDN's EBT Margin at 79261.7% in Q1 2026, 75234.09% in Q4 2025, and 49.67% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - | -44,396.13% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -44,396.13% |
| Mar 31, 2026 | -85,559.57% |
| Dec 31, 2025 | -89,575.00% |
| Sep 30, 2025 | -49.67% |
| Jun 30, 2025 | -134,313.33% |
| Mar 31, 2025 | -130,779.17% |
| Dec 31, 2024 | -110,373.61% |
| Sep 30, 2024 | -88,946.51% |
| Jun 30, 2024 | -101,333.33% |
| Mar 31, 2024 | -79,429.17% |
| Dec 31, 2023 | -92,593.06% |
| Sep 30, 2023 | -66,194.44% |
| Jun 30, 2023 | -76,476.39% |
| Mar 31, 2023 | -69,541.84% |
| Dec 31, 2022 | -43,604.76% |
| Sep 30, 2022 | -2,418.83% |
| Jun 30, 2022 | -11,519.92% |
| Mar 31, 2022 | -11,894.91% |
| Dec 31, 2021 | -13,526.17% |
| Sep 30, 2021 | -6,751.44% |